Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Public ClinicalTrials.gov record NCT06293898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
Study identification
- NCT ID
- NCT06293898
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- SystImmune Inc.
- Industry
- Enrollment
- 280 participants
Conditions and interventions
Conditions
Interventions
- BL-M07D1 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 8, 2024
- Primary completion
- Dec 14, 2028
- Completion
- Apr 14, 2029
- Last update posted
- Mar 22, 2026
2024 – 2029
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| City of Hope | Duarte | California | 91010 | Recruiting |
| Cedars Sinai | Los Angeles | California | 90211 | Recruiting |
| Scripps Health | San Diego | California | 92121 | Not yet recruiting |
| University of Miami | Miami | Florida | 33136 | Recruiting |
| Sarah Cannon Research institute - Lake Nona Florida | Orlando | Florida | 32827 | Recruiting |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | Recruiting |
| University of Illinois Cancer Center | Chicago | Illinois | 60612 | Recruiting |
| University of Chicago Medicine | Chicago | Illinois | 60637 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Karmanos Cancer Institiute | Detroit | Michigan | 48201 | Recruiting |
| NYU Langone Hospital - Long Island Investigational Pharmacy | Mineola | New York | 11501 | Recruiting |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | Recruiting |
| Providence Portland Medical Center | Portland | Oregon | 97213 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| Oncology Consultants | Houston | Texas | 77030 | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06293898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06293898 live on ClinicalTrials.gov.